Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and central nervous system- (CNS) targeted science.
The company lists key differentiators, including:
- Approximately nine times higher bioavailability at peak plasma concentration versus naïve resveratrol
- No gastrointestinal (GI) side effects observed at therapeutic levels
- Secured intellectual property in the U.S., EU, China, Japan, and Hong Kong through 2036
- Demonstrated ability to reach the CNS by passing the blood brain barrier, a critical factor for diseases such as Parkinson’s, Alzheimer’s, and MELAS
In a statement, Christer Rosén, Chairman and CEO of Jupiter, commented, “Clinical studies have shown that to reach the minimum effective plasma concentration of over 250 ng/mL a patient would need to ingest approximately 5 grams of today’s marketed resveratrol products. At those levels, severe GI issues are nearly guaranteed, effectively halting any realistic therapeutic use.”
